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Summary.-The antitumour agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carbox-
amide (DTIC) was found to inhibit competitively the low-Km cyclic AMP phospho-
diesterase activity in an ammonium-sulphate-precipitable fraction of the 2,000g
supernatant of rat liver. With substrate concentration at 0-25 [M, 150 was 790 /tM for
DTIC and 350 tM for theophylline. DTIC at 2 mm more than doubled the cAMP
response to glucagon in hepatocytes and to adrenaline in MH1Cj hepatoma cells,
indicating that it also exerts its inhibitory effect on the phosphodiesterase in intact
cells. The possible contribution of the phosphodiesterase inhibition to the growth-
inhibitory and cytotoxic effects of DTIC is discussed.
UNDER CERTAIN CONDITIONS, high intra-
cellular concentrations of cyclic 3',5'-
adenosine monophosphate (cAMP) inhibit
cell proliferation. Although the role of
this nucleotide in the physiological growth
regulation is still unclear and probably
diverse, it has been firmly established that
in several cultured cell lines proliferation
is inhibited if the intracellular level of
cAMP is artificially raised (Pastan et al.,
1975; Friedman, 1976). It is conceivable,
therefore, that drugs altering cAMP levels
might contribute to pharmacological con-
trol of cancer-cell proliferation.
There is some evidence that certain anti-
tumour drugs already in clinical use inter-
fere with cAMP metabolism. Thus, Tisdale
& Phillips (1975a, b) have shown that
several alkylating antitumour agents in-
crease intracellular cAMP in Walker
carcinoma cells in vitro, probably owing
to inhibition by these drugs ofthe low-Km
form of the phosphodiesterase that breaks
down cAMP (Tisdale, 1974). Recently,
Rudolph et al. (1977) and Kotani et al.
(1978) have shown that colchicine and the
vinca alkaloids vincristine and vinblastine
also raise cellular cAMP levels in leuco-
cytes and lymphoma cells.
We here show that another antitumour
agent, 5- (3,3-dimethyl- 1 -triazeno)imid-
azole-4-carboxamide (DTIC) is able to
inhibit the low-Km form of cAMP phos-
phodiesterase of rat liver, and to amplify
the cAMP response of isolated intact
hepatocytes and cultured hepatoma cells
to hormones.
MATERIALS AND METHODS
Materials. - 5-(3,3-dimethyl-1-triazeno)
imidazole-4-carboxamide (DTIC) was pro-
vided by Dome Laboratories, West Haven,
Conn., U.S.A. cAMP was from Sigma
Chemical Co., St Louis, U.S.A., glucagon
from Novo, Copenhagen, Denmark, and
adrenaline bitartrate from Rhone Poulenc,
Paris, France. Collagenase (CLS II) was from
Worthington Biochemical Corp., Freehold,
N.J., U.S.A., and Dulbecco's modified Eagle's
medium (powder) from Gibco, Grand Island,
N.Y., U.S.A.
Stock solutions of DTIC (80 mM) were pre-
pared by dissolving it in 100mM HC1 imme-
diately before the incubations. Pure DTIC
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and the stock solutions were kept protected
from light.
Assay of cAMP phosphodiesterase.-Adult
male Wistar rat liver was homogenized with
a Potter-Elvehjem glass-teflon homogenizer
in a buffer containing 100mM tris-HCl (pH
7 5) and 4mM MgCl2. The homogenate was
centrifuged at 2000 g for 10 min, and the
supernatant was treated with (NH4)2S04 to
give 55%. The fraction precipitated by
(NH4)2S04 was dissolved by dialysing it over-
night with two changes against the tris buffer,
and stored in aliquots at -80°C. Unless other-
wise stated, this preparation was used as the
enzyme source in the phosphodiesterase
reactions.
The phosphodiesterase assay was carried
out essentially as described previously
(Christoffersen et al., 1973). The reaction was
run at 30'C in a final volume of 400 ,ul in
100mM tris-HCl (pH 7.5) and 4mM MgCi2.
The enzyme activity was measured at various
times at various concentrations of cAMP,
with [3H]cAMP (-10,000 ct/incubate). The
amount of enzyme per incubate was varied
between 75 and 1500 ,tg protein, according to
the substrate concentration. The reaction
was terminated by heating at 95°C for 2 min.
[14C]cAMP (- 5000 ct/min/tube) was added
for recovery determination. The cAMP re-
maining after the incubation was isolated by
paper chromatography as previously de-
scribed (Christoffersen et al., 1973) and
counted by liquid scintillation. In kinetic
analyses, estimation of initial reaction
velocity was based on several incubation
times and extrapolating to zero.
Cells8 used.-Previously described pro-
cedures were used for hepatocyte isolation
(Berg et al., 1972; Seglen, 1972; Christoffersen
& Berg, 1974) and incubation (Christoffersen
& Berg, 1975). Cell viability, determined by
trypan-blue exclusion, was 95-97%. The
incubation buffer contained: 1190mM NaCl,
3 OmM KCl, 2 OmM CaC12, 1 2mM MgSO4,
2-4mM KH2PO4, 24-9mM NaHCO3, with
10mM glucose (pH=7-4). The reaction was
terminated by addition oftrichloroacetic acid
(3.3% final).
MH1Cj hepatoma cells (Richardson et al.,
1969) were obtained from the American Type
Culture Collection, Rockville, Md, U.S.A.
The cells were cultured as incomplete mono-
layers in Falcon plastic flasks (75 cm2), in
lOml Dulbecco's modified Eagle's medium,
supplemented with 10% horse serum, 2-5%
foetal calf serum, penicillin (100 u/ml),
streptomycin (0-1 mg/ml) and nystatin
(60 u/ml). Medium change was at 3-4 days
and subculturing at 7 days. The cells were
used for experiments 7 days after seeding,
when they were nearly fully grown. Incuba-
tions were done in the culture medium
described above, and the reactions were
stopped by addition of 5% trichloroacetic
acid, after rapid removal of medium and
washing (twice) of the cell layers with saline.
Determination of cAMP.-The samples
were centrifuged, and the trichloroacetic acid
in the supernatants was neutralized with
CaCO3, as described by Tihon et al. (1977).
cAMP was measured by a radioimmunoassay
(Steiner et al., 1969) using acetylation of the
samples (Harper & Brooker, 1975; Frandsen
& Krishna, 1976) and acetylated [3H]cAMP
as ligand (Skomedal et al., 1977).
Other procedures.-Protein was determined
by the method of Lowry. Cells were counted
with a Burker haemacytometer.
RESULTS
Effects onphosphodiesterase
As shown in Table I, DTIC inhibited the
breakdown of cAMP in a rat liver 40,00Og
supernatant, when a low concentration
(0-25 ,tM) of substrate was used to allow
measurement ofthe low-Km form(s) ofthe
cAMP phosphodiesterase. DTIC did not
seem to affect the high-Km form, as no
inhibition was seen with the use of 2mM
cAMP as substrate (Table I).
DTIC inhibited the low-Km phospho-
TABLE I.-Effect of DTIC on cAMP
phosphodiesterase activity in rat-liver
supernatant*
nmol cyclic AMP
hydrolysed/mg protein/20 min
High substrate Low substrate
conc.t conc.t
No addition 182-7 + 8-8 0-941 + 0-020
DTIC, 1 mM 182-1l+10-2 0-688 + 0-019
DTIC, 2 mM 173-6+11-6 0-461 + 0 033
* A 40,000g supernatant was used. The values
represent mean + s.e. of 3-5 determinations.
t Initial conc. 2mM cAMP; 520 ,ug protein per
incubate.
t Initial conc. 0-25/tM cAMP; 52 itg protein per
incubate.
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FIG. 1. Double reciprocal plot of tie cAMP
phosphodiesterase activity ofan ammonium
sulphate-precipitable fraction of the 2000g
supernatant (see Methods) from rat liver,
measured at substrate concentration be-
tween 0 073 an(I 10-5 EuM.
diesterase in various preparations of rat
liver (data not shown). Routinely, an
ammonium-sulphate-precipitated 2000g
supernatant, prepared as described above,
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was used. The hydrolysis of cAMP in that
preparation is shown as a double reciprocal
plot in Fig. 1. Using substrate concentra-
tions in the low range (50nM-10M), the
data indicated two components of enzyme
activity, with K,,m at about 0 6 tM and
2-5 MM.
Some characteristics of the inhibition
by DTIC are given in Fig. 2 A-C. Fig. 2B
shows dose-response curves for DTIC and
theophylline, using 0 25 MM of substrate.
5000 inhibition was obtained at 790 /LM for
DTIC and at 350 /tM for theophylline. The
inhibition by DTIC apparently did not
require a preincubation period, as it was
evident from the beginning of the incuba-
tion (Fig. 2A). This differs from the
phosphodiesterase inhibition produced by
the alkylating agent chlorambucil, which
involves a progressive time-dependent
change of the enzyme in presence of the
drug (Tisdale, 1974). A number of experi-
ments under various conditions indicated
that the inhibition by DTIC was almost
entirely of the competitive kind. Hoftsee
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FIG. 2. Inhibitory effect of DTIC on cAMP phosphodiesterase activity in an ammonium sulphate-
precipitable fraction of the 2000g supernatant of rat liver. A: Time course of the phosphodiesterase
reaction in the absence ( O ) or presence ( * ) of 2mM DTIC, at 0-25Mt cAMIP as initial
substrate concentration. B: Dose-response relationslhip for the effect of DTIC (0) on the phospho-
diesterase activity, with theophylline (A) for comparison. The comparison of activ-ities was basecd
on 5min incubations. Substrate concentration 0 25)um. C: Hofstee plot of tile inhilbition by DTIC
of the phosphodiesterase activity, measured at substrate concentration 0 25umM, withouit (a), or
with 0 5mAi (b) or 2mmi (c), D)TIC.
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plots of one experiment are given in
Fig. 2C.
DTIC was protected from light until
added to the reaction vials, but the incu-
bations were not run in the dark. It is
unlikely that extensive photodecomposi-
tion will occur within the time-span of
incubation (Beal et al., 1976), and the
inhibition was immediately manifest. Con-
trol experiments showed that DTIC ex-
posed to sunlight or UV for 1 h inhibited
the phosphodiesterase essentially in the
same way as in the standard experiments.
Effects on intact cells
To test whether DTIC also influences
the phosphodiesterase in intact cells, we
investigated its effect on cAMP accumu-
lation in response to hormones in primary
hepatocyte suspensions and MH1C1 hepat-
oma cell monolayers in culture (Table II).
In hepatocyte suspensions, the presence
of 2 mm of either DTIC or theophylline
approximately doubled the increase of
cAMP produced by a supramaximal con-
centration (1.4 ,uM) of glucagon. The cells
TABLE II.-EffectofDTICandtheophylline
on basal and hormone-stimulated cAMP
levels in rat hepatocytes and MH1Cj
hepatoma cells*
pmol cAMP/mg
protein
Additions
None
DTIC (2 mM)
Theophylline (2 mM)
Glucagon (1-4 IM) 2
Glucagon +DTIC 4
Glucagon +theophylline 4
Adrenaline (50 !LM)
Adrenaline +DTIC
Adrenaline +theophylline
He
Cy
2-]
2-6
2-7
20 4
13-6
epato-
ytest MHlClt
1+0-8 0-8+0-2
B+0 3 1-2+0-3
7 + 0 5 11l+ 0-2
t+3-9
5+995
- 2-7_0-3
7-3+0 3
7 0+ 1-0
* The values given are cAMP levels after 10 min
with or without DTIC or theophylline, followed by
1min exposure to hormone. Mean + s.e. of deter-
minations in 5 experiments on each cell type. Note
that the results from the two kinds of cells are not
directly comparable because of different incubation
conditions.
t Incubated as suspensions in Krebs-Ringer
bicarbonate buffer.
t Incubated as monolayers in Dulbecco-Eagle
medium.
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were preincubated with the phospho-
diesterase inhibitors for 10 min, followed
by exposure to glucagon for 60 sec. When
the cells were incubated with DTIC or
theophylline alone (i.e. without glucagon),
only marginal increases in the cAMP
levels were seen.
Similarly, in MH1Cj hepatoma cells,
pretreatment (10 min) with 2mM DTIC or
theophylline led to a 2-3-fold amplification
of the cAMP response to adrenaline (50
,kM, 60sec exposure). In these experiments
the effect of DTIC or theophylline alone
on cAMP levels (i.e. without subsequent
adrenaline exposure) was not examined in
detail, but later studies (Haffner &
Christoffersen, unpublished) have shown
significantly raised cAMP in MH1C1 cells
after DTIC or other phosphodiesterase
inhibitors.
DISCUSSION
These results show that the antitumour
agent DTIC is a competitive inhibitor of
the low-Km form of cAMP phospho-
diesterase, and the ability of DTIC to
amplifyhormone effects on cAMP accumu-
lation in hepatocytes and hepatoma cells
indicatesthattheinhibitionofthephospho-
diesterase is also manifested in intact cells.
Since about 800 [kM was necessary to
achieve 50% inhibition of the phospho-
diesterase, DTIC is apparently not a par-
ticularly potent inhibitor. However, its
potency was of about the same order as
that of the classical (though not very
strong) phosphodiesterase inhibitor theo-
phylline, both as inhibitor in the cell-free
phosphodiesterase assay and in augment-
ing the cAMP response to glucagon and
adrenaline in intact cells.
It is not clear whether this phospho-
diesterase inhibition plays any role in the
antitumour and growth-inhibitory effects
of DTIC. The mechanism of action of this
drug remains obscure, despite much study
(Loo, 1975; Loo et al., 1976; Bono, 1976;
Beal et al., 1976). Several theories have
been proposed, including purine anti-
metabolite action (Loo et al., 1968), re-
lease of an alkylating methyl radical
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(Skibba et al., 1970; Gerulath & Loo, 1972)
and interaction with SH-groups (Yama-
moto, 1969). However, none of these
hypotheses have so far gained definitive
support. The present study of the effects
of DTIC on phosphodiesterase and cAMP
in liver was provoked by the growth-
inhibitory and differentiating effect of
cAMP on many cell types (Pastan et al.,
1975; Friedman, 1976), and by the fact
that several other imidazole and imid-
azolidinone derivatives have been shown
to be cAMP phosphodiesterase inhibitors
(Chasin & Harris, 1976). DTIC inhibits
cells in G1 as well as G2 (Bono, 1976;
Gerulath et al., 1974), which could be
compatible with a cAMP-mediated effect
(Friedman et al., 1976). Furthermore, in
cultured mouse neuroblastoma cells, treat-
ment with DTIC (10 jug/ml) causes in-
creased activity of tyrosine hydroxylase,
choline acetyltransferase and acetylcholin-
esterase (Culver et al., 1977). These effects
of DTIC, which may be considered as
manifestations of biochemical differentia-
tion of the neuroblastoma cells, are also
seen after dibutyryl cAMP administration
(Prasad, 1975). However, the increase of
these enzyme activities after DTIC were
not accompanied by any demonstrable
increase in cAMP level or inhibition of
phosphodiesterase activity in the study
by Culver et al. (1977) with 10 [kg/ml of
DTIC. With the concentrations of DTIC
used here, the phosphodiesterase was
inhibited. Further studies (Haffner &
Christoffersen, unpublished) have shown
potentiation of cAMP responses to
adrenaline in MH1Cj cells by DTIC at
20 ,ug/ml.
There is some evidence that certain
metabolites of DTIC may be responsible
for the growth-inhibitory effects of the
drug. DTIC is partly demethylated in vivo
to yield the monomethyl derivative
(MTIC; Skibba et al., 1970), which is also
growth-inhibitory, although it is unclear
whether the amount formed is sufficient
to account for the effects of DTIC (Beal
et al., 1976). The role of other degradation
products formed by photodecomposition
and possibly also in vivo has been dis-
cussed (Loo, 1975; Loo et al., 1976). It will
thus be of interest to examine the effect
on cAMP metabolism of various metab-
olites and analogues of DTIC. Further
investigations are necessary to clarify
whether cAMP is involved in any aspect
of the cytotoxic effect of DTIC. Such
studies might also contribute to the
understanding of the potential in cancer
treatment of substances that act on the
cAMP system.
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